1. ElSohly MA, Radwan MM, Gul W, et al. Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod 2017; 103: 1-36.
2.
Mechoulam R, Gaoni Y. A total synthesis of dl-δ1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 1965; 87: 3273-3275.
3.
Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
4.
Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
5.
Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
6.
Huang H, McIntosh AL, Martin GG, et al. FABP1: A novel hepatic endocannabinoid and cannabinoid binding protein. Biochemistry 2016; 55: 5243-5255.
7.
Bouaboula M, Rinaldi M, Carayon P, et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 1993; 214: 173-180.
8.
Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742-755.
9.
Almogi-Hazan O, Or R. The endocannabinoid system and immunity-the journey from the bedside to the bench and back. Int J Mol Sci 2020; 21: 4448.
10.
Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: an overview. Immunobiology 2010; 215: 588-597.
11.
Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12: 671-676.
12.
Patsenker E, Stoll M, Millonig G, et al. Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Mol Med 2011; 17: 1285-1294.
13.
Long C, Xie N, Shu Y, et al. Knockout of the cannabinoid receptor 2 gene promotes inflammation and hepatic stellate cell activation by promoting A20/nuclear factor-κB (NF-κB) expression in mice with carbon tetrachloride-induced liver fibrosis. Med Sci Monit 2021; 27: e931236.
14.
Siegmund SV, Uchinami H, Osawa Y, et al. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 2005; 41: 1085-1095.
15.
Hézode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42: 63-71.
16.
Hézode C, Zafrani ES, Roudot-Thoraval F, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134: 432-439.
17.
Horn H, Böhme B, Dietrich L, et al. Endocannabinoids in body weight control. Pharmaceuticals (Basel) 2018; 11: 55.
18.
Alderman B, Hui D, Mukhopadhyay S, et al. Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer. Support Care Cancer 2022; 31: 39.
19.
Levy C, Galenbeck E, Magid K. Cannabis for symptom management in older adults. Med Clin North Am 2020; 104: 471-489.
20.
Johnson S, Ziegler J, August DA. Cannabinoid use for appetite stimulation and weight gain in cancer care: Does recent evidence support an update of the European Society for Clinical Nutrition and Metabolism clinical guidelines? Nutr Clin Pract 2021; 36: 793-807.
21.
Badowski ME, Perez SE. Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. HIV AIDS (Auckl) 2016; 8: 37-45.
22.
Andries A, Frystyk J, Flyvbjerg A, Støving RK. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int J Eat Disord 2014; 47: 18-23.
23.
O’Sullivan SE, Yates AS, Porter RK. The peripheral cannabinoid receptor type 1 (CB1) as a molecular target for modulating body weight in man. Molecules 2021; 26: 6178.
24.
Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
25.
Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-648.
26.
Gary-Bobo M, Elachouri G, Scatton B, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69: 471-478.
27.
Gary-Bobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic
28.
syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46:
29.
122-129.
30.
Deveaux V, Cadoudal T, Ichigotani Y, et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 2009; 4: e5844.
31.
Agudo J, Martin M, Roca C, et al. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 2010; 53: 2629-2640.
32.
De Gottardi A, Spahr L, Ravier-Dall’Antonia F, et al. Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes. Liver Int 2010; 30: 1482-1489.
33.
Denaës T, Lodder J, Chobert MN, et al. The cannabinoid receptor 2 protects against alcoholic liver disease via a macrophage autophagy-dependent pathway. Sci Rep 2016; 6: 28806.
34.
Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012; 12: 436-444.
35.
De Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 1998; 95: 8375-8830.
36.
Melck D, Bisogno T, De Petrocellis L, et al. Cannabimimetic eicosanoids in cancer and inflammation: an update. Adv Exp Med Biol 2002; 507: 381-386.
37.
Vara D, Salazar M, Olea-Herrero N, et al. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 2011; 18: 1099-1111.
38.
Rao M, Chen D, Zhan P, Jiang J. MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway. Biol Direct 2019; 14: 9.
39.
Suk KT, Mederacke I, Gwak GY, et al. Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut 2016; 65: 1721-1732.
40.
Avraham Y, Israeli E, Gabbay E, et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol Dis 2006; 21: 237-245.
41.
Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 1988; 8: 232-236.
42.
Bátkai S, Járai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-832.
43.
Rajesh M, Bátkai S, Kechrid M, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012; 61: 716-727.
44.
An D, Peigneur S, Hendrickx LA, Tytgat J. Targeting cannabinoid receptors: Current status and prospects of natural products. Int J Mol Sci 2020; 21: 5064.
45.
Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs 2006; 15: 307-315.
46.
Wang L, Liu J, Harvey-White J, et al. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A 2003; 100: 1393-1398.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
